Recent developments of interest in cardiovascular medicine
The FDA's inspection of a number of plants in India that make the active pharmaceutical ingredients for valsartan, losartan, and irbesartan turned up none of the cancer-related NDMA (N-Nitrosodimethylamine) contaminant that has led to recent recalls from other companies. (in-Pharma Technologist.com)
National healthy survey data says that 24.7% of U.S. adults are on aspirin for primary cardiovascular prevention, according to the CDC's Morbidity and Mortality Weekly Report -- notable after the ASCEND and ARRIVE data suggesting that the risk-benefit tradeoff doesn't pay off. Overall, the data indicate that management of cardiovascular risk factors has stalled, Cardiovascular Business reports.
Pioneering interventional cardiologist Joseph D. Babb, MD, died recently at the age of 79. The Society of Cardiovascular Angiography and Interventions offered a remembrance for its past president.
A musician is working with Medtronic to redesign the soundscape of home cardiac device monitors. (STAT News)
Heart patients shouldn't take any weight-loss or energy supplements containing the stimulant higenamine, a study warned in Clinical Toxicology. (Cardiovascular Business)
An 86-year-old blogger's account of her medicalized life after getting atrial fibrillation is on CardioBrief.
Part of the problem with Baylor St. Luke's heart transplant program that led the Centers for Medicare & Medicaid to reject it may have been a "a retiring surgeon" who "wouldn't stop performing transplants," leading to a rash of patient deaths, ProPublica reports.
Oregon Health & Science University suspended its heart transplant program after a staff shortage as at least three cardiologists on the transplant team left or said they were leaving. (The Oregonian/OregonLive)
People recovering from sepsis are at two- to five-fold elevated risk of myocardial infarction or stroke in the first month after discharge. (CMAJ)
A blood test panel plus personal history of hypertension plugged into the artificial intelligence-powered HART PAD test predicted peripheral arterial disease in diabetes with high accuracy in the CASABLANCA study presented at the European Society of Cardiology meeting in Munich. (Endovascular Today)
Percutaneous coronary intervention outcomes are still worse for women, even after adjusting for the "significant sex-based differences in presentation, baseline characteristics, and comorbidity burden," a national study showed in PLOS One.
Read the original article on Medpage Today: ARBs from India Safe; Aspirin Primary Prevention; Energy Pill Risk